Triamterene (traded under names such as Dyrenium and Dytac) is a potassium-sparing diuretic often used in combination with thiazide diuretics for the treatment of high blood pressure or swelling. The combination with hydrochlorothiazide, is known as hydro + some more technical info. Chemically it is a pteridine derivative that acts at the late distal tubule and cortical collecting duct to reduce sodium reabsorption and limit potassium loss; clinical formulations are typically immediate-release oral tablets and fixed-dose combinations with thiazide agents, with pharmacokinetic properties including oral absorption, hepatic biotransformation to hydroxylated and deaminated metabolites, high plasma protein binding, and predominantly renal elimination of parent drug and metabolites.
Parent: Triamterene
Parent: Triamterene
Parent: Triamterene
Typical active pharmaceutical ingredient specifications set assay acceptance around 98.0 to 102.0 percent by validated HPLC, with individual unspecified impurities commonly limited to not more than 0.2 or 0.5 percent and total impurities not to exceed about 1.0 percent, while any single identified related compound is often restricted to 0.1 to 0.2 percent depending on toxicological qualification; key related compounds and degradants to monitor by stability and forced-degradation studies include hydroxylated metabolites, deaminated species, N-oxide or oxidized pteridine derivatives, ring-opened or hydrolytic products, and trace synthetic residuals or isomeric impurities (for example desalkylation or positional isomers), all typically quantified by HPLC-UV or LC-MS methods with system suitability and validated limits.
Triamterene is used to promote diuresis while conserving potassium, most commonly combined with a thiazide diuretic to treat hypertension and edema associated with heart failure, cirrhosis, or renal salt retention; the combination reduces thiazide-induced hypokalemia.
Triamterene directly inhibits epithelial sodium channels in the late distal tubule and cortical collecting duct, decreasing sodium influx into principal cells, which reduces the driving force for potassium secretion and thereby spares potassium.
No, triamterene is not a thiazide; it is a potassium-sparing agent with a pteridine scaffold and a distinct mechanism that targets epithelial sodium channels, whereas thiazides inhibit the NaCl cotransporter in the distal convoluted tubule.
Both are potassium-sparing diuretics but differ mechanistically and pharmacologically: triamterene is an epithelial sodium channel blocker with a relatively rapid onset and direct tubular action, while spironolactone is an aldosterone receptor antagonist that alters transcriptional regulation of sodium and potassium transport and has a slower onset; spironolactone is a steroidal agent with potential endocrine side effects such as gynecomastia, whereas triamterene does not have those steroid-related effects but carries its own risk profile including hyperkalemia and potential crystalluria in susceptible patients.
